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Abstract Sporadic inclusion body myositis (IBM) is an ac-
quiredmuscle disorder associatedwith ageing, for which there is
no effective treatment. Ongoing developments include: genetic
studies that may provide insights regarding the pathogenesis of
IBM, improved histopathological markers, the description of a
new IBM autoantibody, scrutiny of the diagnostic utility of
clinical features and biomarkers, the refinement of diagnostic
criteria, the emerging use ofMRI as a diagnostic andmonitoring
tool, and new pathogenic insights that have led to novel thera-
peutic approaches being trialled for IBM, including treatments
with the objective of restoring protein homeostasis and
myostatin blockers. The effect of exercise in IBM continues to
be investigated. However, despite these ongoing developments,
the aetiopathogenesis of IBM remains uncertain. A translational
and multidisciplinary collaborative approach is critical to im-
prove the diagnosis, treatment, and care of patients with IBM.
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Introduction
Sporadic inclusion bodymyositis (IBM) is an acquiredmuscle
disease for which there is no effective treatment. IBM has a
male predominance and usually does not affect individuals
below the age of 45. The prevalence of the disease is in the
range 1–71 per million, reaching 139 per million over the age
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of 50 [1–10]. Therefore, IBM belongs to the rare (or orphan)
diseases, defined in the European Union as having a preva-
lence of no more than 5/10,000 people (500 per million) and
defined in the United States of America as having a prevalence
of fewer than 200,000 affected Americans (approximately 6.3/
10,000 people or 630 per million). The rarity of the disease,
lack of patient and clinical awareness, and diagnostic difficul-
ties contribute to a substantial delay between the onset of
symptoms and diagnosis (five-year delay on average)
[11–13, 14•].
The aetiopathogenesis of IBM remains unclear. Historical-
ly it has been included in the group of idiopathic inflammatory
myopathies, with polymyositis (PM), dermatomyositis (DM),
and the immune-mediated necrotising myopathies. However,
IBM is very different from these conditions and is character-
ized by lack of response to immunosuppressant medication,
both inflammatory and degenerative features on muscle biop-
sy, a typical early clinical phenotype with (often asymmetric)
weakness of the knee extensors and finger flexors, potential
involvement of pharyngeal and upper-oesophageal muscles
(which may contribute to malnutrition and aspiration), and
progressive and slow deterioration that may lead to severe
disability and loss of quality of life [12, 13, 14•, 15, 16].
In this article we will review ongoing developments in
IBM, covering the genetic contribution to IBM, recent diag-
nostic developments, and the effect of exercise in IBM, and
discuss new insights into the pathogenesis of the disease and
new therapeutic approaches, with a focus on targeting protein
dyshomeostasis and inhibiting the myostatin pathway.
Genetic Contribution to IBM
Although it is regarded as a sporadic disease, genetic studies
are important in IBM because they may reveal important
pathways involved in the disease and risk factors that may
increase our understanding of this disorder and identify po-
tential therapeutic targets. There are three genetic approaches
best suited to studying IBM:
1. candidate gene analysis, on the basis of clinico-
pathological features;
2. genetic analysis of small families with IBM or very sim-
ilar clinical and pathological phenotypes; and
3. large-scale genome-wide association study (GWAS) and
exome-sequencing approaches [17••].
Candidate Gene Studies Have Provided Evidence of Genetic
Susceptibility in IBM
Major histocompatibility complex (MHC) associations still
provide the strongest evidence for a genetic component to
IBM. The strong association of the extended 8.1 ancestral
haplotype (AH) with IBM has been reported in a series of
studies on different Caucasian populations [18–26]. Other
alleles and haplotypes have also been associated with in-
creased risk of IBM, including 35.2AH [22] and 52.1AH
[27] for Caucasians and Japanese populations, respectively.
Furthermore, two polymorphisms (rs422951 and rs72555375)
of the NOTCH4 gene in a susceptibility region for IBM with
MHC (from BTNL2 to HLA-DRB1) [28] also had a strong
association (OR >2) with IBM in two independent Caucasian
cohorts [29]. Further investigations are required to determine
whether these genes are directly involved in the disease path-
ogenesis. Recently, an autoantibody against the cytoplasmic
5′-nucleotidase 1A (cN1A; NT5C1A) was identified in IBM
[30••, 31••]. Although no protein-coding mutation was found
in a small group of patients, NT5C1A and its related genes
remain important candidate genes for future investigation.
Research on candidate genes has also focused on the genes
encoding the aggregated proteins or proteins related to neuro-
degenerative disease. Studies have included, for example,
beta-amyloid precursor protein (APP) [32, 33], apolipoprotein
E (APOE) [34], phosphorylated Tau (MAPT) (unpublished
data), alpha-1-antichymotyrpsin (SERPINA3) [35], prion pro-
tein (PRNP) [36–38], TAR DNA-binding protein-43 (TDP-
43; TARDBP) [39–41], and C9orf72 (unpublished data).
However, no associations between these genes and IBM have
yet been established.
Mutations in mitochondrial DNA (mtDNA) have also been
investigated.Multiple mtDNA deletions have been reported in
many cytochrome-c-oxidase (COX)-deficient ragged-red fi-
bres of IBM patients [42–44]. Mutations of mitochondrial
encoded nuclear genes, including TYMP, SLC25A4 (previous-
ly known as ANT1), C10orf2, and POLG1, had previously
been associated withmultiple mtDNA deletions, and therefore
these genes were studied; however, no mutations were found
in five IBM patients [45]. Interestingly, an intronic polymor-
phism (rs10527454, described as ‘rs10524523’ in currently
published papers) in a gene called “translocase of outer mito-
chondrial membrane 40” (TOMM40) which is adjacent to and
in linkage disequilibrium with the APOE locus on chromo-
some 19 [46], together with the APOE genotypes, has been
revealed to affect IBM disease susceptibility [47].
Genes Identified in Familial or Hereditary IBM, and Other
Vacuolar and IBM-Like Myopathies, Also Provide Important
Insights for IBM Genetic Research
Table 1 summarises the genes identified in familial or hered-
itary IBM that may provide insight for IBM genetic research
[17••, 48–50]. In a Japanese study, the p.V805A variant in
myosin heavy chain IIa (MYH2) (gene associated with
hIBM3) significantly increased the risk of developing IBM
(RR =12.2) in a group of 21 patients [51].
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Exome, Genome, and GWAS Approaches
Although IBM is not an inherited Mendelian disease, multiple
genetic risk factors have been proposed to have important
functions in the development and progression of IBM. The
advent of more robust genetic approaches, for example whole-
exome sequencing, has enabled the identification of rare cod-
ing variants which may be functional, increasing the probabil-
ity of detecting disease-associated variants. This is particularly
important for such rare diseases as IBM, where the number of
cases is probably not large enough for a conventional GWAS.
Our group is currently collecting IBM samples in an exome-
sequencing project to perform an approach to identify novel
risk pathways. We have exome sequenced more than 100 IBM
cases and we hope to increase this number through collabora-
tion with neurologists and rheumatologists around the world.
Histopathological Findings and Their Diagnostic Use
In addition to the inflammatory changes observed, muscle
biopsy in IBM reveals a wide range of pathological features
including variation in fibre size, rounded and angulated atro-
phic fibres, increased numbers of internal nuclei, mitochon-
drial changes including COX-negative fibres and ragged-red
fibres, and increased endomysial connective tissue.
Historically, diagnostic criteria for IBM have depended
heavily upon the observation of specific pathological findings
on muscle biopsy. The seminal Griggs criteria were the first
widely adopted diagnostic criteria for IBM [52]. Using these
criteria, a diagnosis of definite IBM could be made solely on
the basis of the following pathological findings: an auto-
aggressive inflammatory myopathy with invasion of morpho-
logically normal fibres (so called partial invasion), rimmed
vacuoles (irregular vacuoles within a muscle fibre surrounded
by or containing basophilic granular material with
haematoxylin and eosin staining, or staining red with Gomori
t r i c h r ome ) , and e i t h e r amy lo i d o r 15–18 nm
tubulofilamentous inclusions visualised with electron micros-
copy (EM). These pathological findings, in isolation, are
found in other myopathies; however, in combination they
are regarded as highly specific for IBM. The recognition of
the characteristic clinical presentation associated with IBM
has revealed that these diagnostic pathological features may
be absent in patients with clinically typical IBM [14•, 53]. One
study found that more than 40 % of patients lacked the
necessary diagnostic pathological features on light microsco-
py at presentation, and lent support to the theory that the
limited sensitivity of the pathological features included in
the Griggs criteria is because they are associated with chro-
nologically more advanced disease [54].
Immunohistochemical staining techniques have clarified
the composition of the inflammatory infiltrate in IBM [55],
revealed the widespread sarcolemma and sarcoplasmic upreg-
ulation of MHC class I (MHC-I) [56••], and identified the
pathological accumulation of many proteins within muscle
fibres in IBM. The proteinsmost frequently described include:
proteins more commonly associated with neurodegenerative
diseases, namely β-amyloid, phosphorylated tau, and ubiqui-
tin; the myofibrillar-myopathy-associated proteins myotilin
and αB-crystallin; and the newer neurodegenerative markers
p62 and TDP-43. However, some of these findings have not
been consistently reproduced, leading to uncertainty and ques-
tions over their significance [57].
Despite a lack of data on the diagnostic utility of the
pathological findings, most expert muscle pathologists agree
that histochemical staining for mitochondrial changes and
immunohistochemical staining aid in differentiating IBM
from pathologically similar myopathies. Two recent quantita-
tive studies examined the sensitivity and specificity of patho-
logical features in IBM. The first recommended a combination
of LC3 and TDP-43 staining: <14 % LC3-positive fibres
helped to exclude a diagnosis of IBM, and >7 % TDP-43-
positive fibres supported a diagnosis of IBM [58•]. The main
limitation of this study was a lack of clinical data. A subse-
quent study assessed the diagnostic utility of markers of
protein aggregation, inflammation, and mitochondrial chang-
es [56••]. The authors proposed a pathological diagnostic
algorithm to differentiate IBM with rimmed vacuoles from
other vacuolated myopathies (sensitivity 93 %, specificity
100 %) and IBM without rimmed vacuoles from steroid-
responsive inflammatorymyopathies (sensitivity 100%, spec-
ificity 73 %). An additional finding was that the morphology
of p62 aggregates in IBM was consistent and may aid in
differentiating IBM from pathological mimics.
Autoantibodies
Autoantibodies against cN1A are a new serological marker for
IBM [30••, 31••, 59]. With their high specificity and moderate
Table 1 Genes identified in familial or hereditary IBM that may provide
insights for IBM genetic research
IBM-like diseases Genes
Familial IBM HLA-DR3 allele (DRB*0301/0302);
HLA-DR15(2)/DR4 (DRB1*1502/0405)
Hereditary IBM GNE (OMIM#603824); LAMA2
(OMIM#156225); MYH2 (OMIM#160740);
VCP (OMIM#601023)
Other rimmed vacuolar
myopathies
PABPN1 (OMIM#602279); EMD
(OMIM#300384); MYOT (OMIM#604103);
TCAP (OMIM#604488); SEPN1
(OMIM#606210)
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sensitivity for IBM, anti-cN1A antibodies may be particularly
useful in the differential diagnosis of recent-onset myopathies
and/or myositis. Interestingly, the anti-cN1A response has
been revealed to consist of a variety of immunoglobulin
classes, and this could also be of diagnostic value [60]. Using
absorbance units (AU) to measure anti-cN1A reactivity, an
IgG cut-off >0.9 AU had 51 % sensitivity and 94 % specific-
ity, an IgA cut-off >1.2 AU had 49 % sensitivity and 95 %
specificity, and an IgM cut-off >1.9 AU had 53 % sensitivity
and 96 % specificity for diagnosing IBM in a population of
205 individuals: 50 with IBM, 121 with another neuromuscu-
lar disease, and 34 healthy controls. By testing several thresh-
olds and combining the three isotypes, it was possible to
increase sensitivity to 76 %, with only a slight reduction in
specificity (91 %), using the following combination of cut-
offs: IgG >1.3 AU or IgA >1.1 AU or IgM >1.9 AU [60].
MRI Assessment
Muscle MRI is increasingly recognised as a useful assessment
in the diagnostic pathway of inherited muscle disease [61]. In
IBM patients both signal hyperintensity within muscles on
T1-weighted sequences, caused by intramuscular fat accumu-
lation, and hyperintensity caused by muscle oedema on T2-
weighted sequences with fat suppression, for example the
short tau inversion recovery (STIR) sequence, are observed
(Fig. 1). A selective pattern of muscle involvement has been
reported. Similar to the clinical presentation, within the fore-
arm there is preferential intramuscular fat accumulation within
the flexor digitorum profundus [62, 63•, 64, 65]; whereas in
the thigh the quadriceps femoris is preferentially affected [63•,
64, 66], with some authors reporting relative preservation
within the quadriceps of the rectus femoris [63•, 64]. Within
the lower leg, the medial head of the gastrocnemius consis-
tently has maximal intramuscular fat accumulation [63•, 64,
66]; a feature not apparent clinically as ankle plantar flexion
weakness, because the soleus and the lateral gastrocnemius
have lesser involvement. STIR hyperintensity reflecting active
inflammation within the muscle is commonly seen, but in a
smaller number of muscles than are affected by fat accumula-
tion [62, 63•, 65]. Although this typical pattern of involvement
is well described, the diagnostic sensitivity and specificity of
MRI in IBM has not been systematically assessed and MRI
appearances are not currently included in IBM diagnostic
criteria.
In addition to this potential function in the diagnosis of
muscle disease,MRI shows much promise as a tool tomonitor
disease progression and provide sensitive outcome measures
for clinical trials. MRI is able to quantify intramuscular fat
accumulation with the three-point Dixon sequence [67] most
commonly used. Acute pathology can be quantified by mea-
suring increases in T2 within muscle; these may be reversible
with effective therapy, as revealed for periodic paralysis [68].
These quantitative MRI methods have been revealed to have
good reliability for healthy volunteers [69]. In IBM patients,
intramuscular fat accumulation within the quadriceps has a
strong negative correlation to knee-extension strength [70].
Unlike strength testing, MRI is independent of subject effort,
so may provide more responsive measures of disease progres-
sion than direct myometric assessment. Performance of MRI
outcome measures should be defined in IBM natural-history
studies before application in clinical trials.
Research Diagnostic Criteria
The 2011 European Neuromuscular Centre (ENMC) criteria
were published in 2013 and are the latest IBM research
diagnostic criteria [71•]. They build on the previously pub-
lished MRC Centre criteria [72, 73]. In the presence of the
appropriate clinical phenotype, the ENMC criteria enable
more flexibility regarding the presence of typical histopatho-
logical features. Patients can be divided into three categories:
“clinico-pathologically defined IBM”, “clinically defined
IBM”, and “probable IBM” (Table 2) [71•].
In a retrospective population of 371 patients (200 with and
171 without IBM), specificity was high (98–100 %) for all
three categories. The sensitivity was 15 % for “clinico-patho-
logically defined IBM” and 84 % for the combination of
“clinically defined and probable IBM” [74••]. The overall
sensitivity of the criteria was not reported, but given that
patients with “clinico-pathologically defined IBM” may or
may not satisfy the other two categories, the overall sensitivity
of the criteria should be approximately 90 % (exact value in
the range 84–99%). In another study that included 67 patients
with IBM, the reported sensitivity of the 2011 ENMC criteria
was 88 % [54]. Therefore the 2011 ENMC criteria seem
suitable for selecting patients for clinical trials, particularly if
they are used as a whole (i.e. including all three categories).
Individually, some IBM features perform better than others,
and in the above-mentioned dataset of 371 patients the authors
applied a machine-learning technique to IBM features and
found that a simplified combination of finger-flexion or
knee-extension weakness, endomysial inflammation, and ei-
ther partial invasion or rimmed vacuoles had 90 % sensitivity
and 96 % specificity for IBM [74••].
Aetiopathogenesis
The aetiopathogenesis of IBM is controversial and probably
multifactorial [75–78]. Several pathogenic models have been
proposed, including autoimmunity, protein dyshomeostasis,
myonuclear degeneration, nucleic-acid-metabolism impair-
ment, mitochondrial dysfunction, and a function for
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microRNA and the myostatin pathway [75–86]. Ageing, ge-
netic, and environmental factors may also contribute to dis-
ease aetiopathogenesis.[17••, 78] In this review we will focus
on two models with recent therapeutic implications: protein
dyshomeostasis and myostatin signalling.
Protein Dyshomeostasis: Function in IBM
Mounting evidence suggests that there is disruption of protein
homeostasis in IBM muscle, resulting from impaired protein
degradation by autophagy and the ubiquitin–proteasome sys-
tem (UPS), which may be responsible for the degenerative
pathology observed in affected muscles.
Disruption of the UPS in IBM Muscle
Ubiquitinated proteins are catabolised by the proteasome in
the UPS, the main cellular-protein degradation pathway. In
IBM muscle, two proteins which target ubiquitinated proteins
for degradation, valosin-containing protein (VCP) and p62,
are aggregated in the sarcoplasm [87–90]. Heightened
ubiquitination of proteins and a threefold increase in p62
expression in IBM muscle suggest either an increased need
for protein degradation or impaired UPS or autophagy [90,
91]. Proteasome subunits have also been identified in sarco-
plasmic aggregates [92], and others report a significant reduc-
tion in proteasome function at all of its three catalytic sites [90,
92]. Moreover, immuno-proteasome subunits, which produce
peptides for MHC class I antigen presentation, have also been
detected in affected IBM muscle, linking protein degradation
to inflammation [92]. UBB+1, a mutant form of ubiquitin, is
also expressed in IBM muscle [93], and high levels of UBB+1
may result in proteasome inhibition [93].
Disruption to Autophagy in IBM Muscle
Rimmed vacuoles, a defining characteristic of IBM, have been
associated with abnormal lysosomal activity caused by the
Fig. 1 Typical MRI appearances in a patient with IBM. (a) Axial T1-
weighted images of the mid-thigh (top), distal thigh (middle), and mid-
calf (bottom). The thigh shows intramuscular fat accumulation, evident as
hyperintensity; most notably within the quadriceps (RF: rectus femoris;
VL: vastus lateralis; VM: vastus medialis), especially in the distal thigh.
Hamstring involvement is asymmetric, with semimembranosus (SM)
relatively spared on the left. In the calf the medial gastrocnemius (MG)
is completely replaced by fat, with the soleus (So) also severely affected.
(b) Axial T1-weighted image at mid-thigh of the same patient six years
later shows significant progression of intramuscular fat accumulation,
with only the biceps femoris (BF) relatively unaffected. (c) Axial STIR
images at distal thigh (top) and mid-calf (calf) in the same patient at
baseline. Acute muscle inflammation is evident as hyperintensity, most
markedly in the vastus medialis and soleus
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presence of membranous debris within the vacuoles, and
an increased immuno-reactivity for markers of autophagy
[90]. Autophagy components including LAMP2A and
LC3 II, the autophagosome maturation marker, accumu-
late in IBM myofibres, indicating either an increased
demand for autophagy or an impaired pathway [90, 94,
95]. Askanas and colleagues have identified a 50 %
reduction in activity of lysosomal cathepsin D despite
an increased protein load [90]. Furthermore, they reveal
that levels of NBR1, an autophagy-associated ubiquitin-
binding protein, are increased in IBM-patient muscle,
with the protein aggregated in the sarcoplasm [96]. This
indicates a lack of the functioning components crucial
for efficient autophagy.
The Unfolded-Protein Response (UPR)
The expression levels of five proteins of the unfolded-protein
response (UPR), an acute cellular response to misfolded pro-
teins in the endoplasmic reticulum (ER) (causing ER stress),
are elevated in IBMmuscle [97]. Furthermore, aggregation of
VCP, which extracts and transports ER proteins to the protea-
some, suggests a broken link between the UPR and
proteasomes in IBM [90, 98].
Evidence of Protein Mishandling in IBM
Disruption to the three protein-handling mechanisms de-
scribed above leads to reduced protein clearance, resulting in
protein accumulation and aggregation. The presence of inclu-
sion bodies, large sarcoplasmic filamentous aggregates, is
characteristic of IBM, and more than 50 different proteins
have been associated with these aggregates, including TDP-
43, presenilin1, amyloid β-precursor protein, and phosphory-
lated tau [90]. No single protein has been universally identi-
fied in all IBM muscle or been linked to pathogenesis, sug-
gesting aggregation is non-specific [91]. However, it is possi-
ble that protein aggregation is not simply a diffusion-limited
process, but rather a regulated tool to sequester excessive
cellular proteins, thereby attempting to redress the imbalance
in protein homeostasis [99].
Protein chaperones, for example heat-shock protein 70
(HSP70), bind to aberrant proteins and help prevent aggrega-
tion [100]. An increase in HSP70 expression, and HSP70 and
αB-crystallin immuno-reactivity in IBM inclusion bodies
[90], suggests a diminished capacity of chaperone proteins
to handle the excessive protein load in IBM myofibres. These
findings suggest that approaches with the objective of restor-
ing protein homeostasis may be a successful therapeutic strat-
egy for IBM.
The Myostatin Pathway: Function in IBM
The myostatin pathway is a central negative regulator of
myogenesis during development and periods of muscle
regeneration in postnatal life [101]. Inhibition of this
pathway enhances muscle regeneration in animal models
of muscle disease [16]. Myostatin knockout mice also
have an increase in muscle mass without organ anoma-
lies [102], and a range of myostatin-inhibited animals,
and a human patient with loss-of-function mutations,
have muscle hypertrophy with increased strength
Table 2 2011 European Neuromuscular Centre Inclusion Body Myositis research diagnostic criteria 2011 (adapted from Ref. [71•])
Category Clinical features Pathological features
Clinico-pathologically defined IBM ○ Duration of weakness >12 months
○ Creatine kinase ≤15 × ULN
○ Age at onset >45 years
○ FF weakness > SAweakness and/or KE weakness
≥ HF weakness
All of the following:
○ Endomysial inflammatory infiltrate
○ Rimmed vacuoles
○ Protein accumulationa or 15–18 nm filaments
Clinically defined IBM ○ Duration of weakness >12 months
○ Creatine kinase ≤15 × ULN
○ Age at onset >45 years
○ FF weakness > SAweakness and KE weakness
≥ HF weakness
One or more, but not all, of:
○ Endomysial inflammatory infiltrate
○ Up-regulation of MHC class I
○ Rimmed vacuoles
○ Protein accumulationa or 15–18 nm filaments
Probable IBM ○ Duration of weakness >12 months
○ Creatine kinase ≤15 × ULN
○ Age at onset >45 years
○ FF weakness > SAweakness or KE weakness
≥ HF weakness
One or more, but not all, of:
○ Endomysial inflammatory infiltrate
○ Up-regulation of MHC class I
○ Rimmed vacuoles
○ Protein accumulationa or 15–18 nm filaments
a Evidence of amyloid or other protein accumulation by established methods (e.g. for amyloid Congo red, crystal violet, thioflavin T/S, for other proteins
p62, SMI-31, TDP-43)
FF, finger flexion; HF, hip flexion; KE, knee extension; SA, shoulder abduction; MHC class I, major histocompatibility complex class I; ULN, upper
limit of normal
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[103–106]. Thus this pathway is of major interest as a
target for therapeutic manipulation in neuromuscular con-
ditions characterised by progressive muscle atrophy and
weakness.
After activation, the myostatin peptide of the transforming-
growth-factor-β superfamily binds to the transmembrane
activin receptor IIB (ActRIIB), which in turn activates a Smad
complex that enters the nucleus and activates the transcription
of myogenic genes, inhibiting the proliferation and differenti-
ation of myogenic precursors [107]. During development,
myostatin inhibitors (follistatin, FLRG, and GASP-1) bind
extracellularly, reducing bioavailability [16]. Antibodies to
myostatin [108, 109], a propeptide to maintain its inactive
state [110], a dominant negative myostatin analogue [111],
and soluble ActRIIB [112] have all been designed to block the
myostatin pathway, in addition to using isoforms of follistatin
[113], follistatin gene therapy [113, 114], and the use of
histone deacetylase inhibitors to up-regulate follistatin [115,
116].
Myostatin may be implicated in the pathogenesis of
IBM, as suggested by Wójcik et al. in a study revealing
the accumulation of myostatin in muscle fibres [117].
Myostatin signalling also leads to FOXO/Atrogin-1 induc-
tion [118], mediating atrophy by targeting the myogenic
regulatory factor myoD for degeneration [119]. Nuclear
translocation of the forkhead-family transcription factor
Foxo3A and mRNA induction of the atrophy-related ubiq-
uitin ligase Atrogin-1 have been revealed in IBM and
polymyositis, indicating activation of this pathway [120].
Nonetheless, the central pathogenesis remains to be fully
elucidated in IBM, and targeting this pathway would not
specifically address the known degenerative and inflamma-
tory and/or immune factors.
For example, enhancing regeneration without suppress-
ing dysimmune factors could be counterproductive, as sug-
gested by the potential to elicit autoantibodies to antigens
enriched in regenerating fibres [121]. Furthermore, dysreg-
ulation of the autophaglyosome in IBM [122] may have
consequences for the simultaneous therapeutic promotion
of muscle mass, because the effective synthesis of structural
proteins in aging patients would be essential to long-term
treatment benefits. Also, an underlying problem with en-
dogenous cellular-protective mechanisms (accumulation of
misfolded proteins, endoplasmic-reticulum stress) [97]
could compromise the therapeutic efficacy of myostatin
inhibitors.
Although it has been argued that addressing the underlying
pathogenic process is critical to designing therapy for IBM
[16], promoting skeletal-muscle growth via myostatin inhibi-
tion may still be effective. This could reduce disability for
patients during their lifetime, because IBM is a slowly
progressing disease and potential clinical benefits may out-
pace the rate of functional decline.
IBM Clinical Trials: Targeting Protein Dyshomeostasis
and Inhibiting the Myostatin Pathway
In a recent randomised double-blind placebo-controlled trial
(RDBPCT) [123, 124], up-regulation of the heat-shock re-
sponse (HSR) was tested by treatment with arimoclomol, an
oral pharmacological agent that has been revealed to co-
induce the synthesis of heat-shock proteins (including
HSP70 and HSP90) by augmenting the HSR in cells where
the endogenous HSR has already been initiated.
In this clinical trial, 24 patients were randomised with a 2:1
arimoclomol–placebo ratio. The investigational drug was
administred for four months and arimoclomol was given at a
dose of 100 mg TDS. After a four-month treatment phase
there was an additional eight-month blinded follow-up phase.
No major safety problems were observed during the trial, and
the drug was well tolerated by patients. Efficacy measures
were secondary outcomes. Numerically, the rate of decline in
physical function (IBM functional rating scale) and muscle
strength (right-hand-grip maximum voluntary isometric con-
traction testing and manual muscle testing) was less in the
arimoclomol group compared with placebo, with a stronger
(non-statistically significant) trend at eight months. This pre-
liminary indication of the potential therapeutic benefit of
arimoclomol supports further investigation of this drug for
treating patients with IBM.
Two myostatin antagonists are currently being tested for
IBM. The first approach uses follistatin gene therapy (FS344)
delivered by adeno-associated virus (AAV) and administered
by quadriceps intramuscular injection [125]. This open-label
clinical trial will test the safety of three different doses of
AAV-FS344 (total nine patients, three patients per dose-
treatment group). Measures of muscle strength, physical func-
tion, thigh circumference, MRI assessment, and muscle his-
topathology are secondary outcomes of the study [125].
The second anti-myostatin approach uses a humanised
monoclonal antibody (BYM338/Bimagrumab) that binds to
ActRIIB and therefore blocks the effect of myostatin. The
drug is administered intravenously and was recently tested in
a small single high-dose pilot study [109, 126]. After eight
weeks of drug administration, thigh-muscle volume increased
in the BYM338 group (11 patients) versus placebo (3 patients)
(6.5 % and 7.6 % increase in the right and left thigh, respec-
tively), as did fat-free mass (5.7 % increase). After 16 weeks
of follow-up (with two drop-outs), patients who had been
given the active drug had a 14.6 % increase in their 6 min
walking distance (6MWD) compared with those given place-
bo. All these differences were statistically significant [126].
Bimagrumab is now being tested in a large multicentre
RDBPCT that intends to recruit 240 patients throughout the
world [127]. This phase IIb and III clinical trial will test three
different monthly doses of the active drug versus placebo
(1:1:1:1 ratio). This will be the largest IBM clinical trial to
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date and will last at least one year. The primary outcome
measure is the 6MWD. Several secondary outcome measures
will be evaluated, including muscle strength, lean body mass,
disability, health-related quality of life, rate of fall events,
swallowing function, and safety and tolerability of the drug
[127].
Exercise in IBM
Lack of restorative treatment for IBM means that exercise has
an important function in managing symptoms and reducing
physical inactivity with its associated sequelae [128, 129•].
Although historically people with muscle conditions were
advised not to exercise for fear of increasing damage, in recent
years several small non-randomised studies have revealed
benefits of exercise in neuromuscular conditions [128, 130].
For people with IBM, moderate-intensity strength training
is established as safe (by serum markers of inflammation and
muscle biopsy), with mixed reports on efficacy [131–133].
However, these studies consisted of small cohorts, were het-
erogeneous with respect to disability, and lacked controls and
blinding.
Improved quadriceps muscle strength could potentially
have a positive effect on disability, because it has been re-
vealed to correlate with improved walking and stair-climbing
tests [134]. New approaches also show promise, including a
recent case study reporting increased strength with resistance
training and vascular occlusion for someone who had previ-
ously reached a plateau [135]. However, quadriceps strength
as a surrogate marker has yet to be validated, and good quality
randomised controlled trials are needed to determine the best
type, dose, and intensity of training.
Aerobic deconditioning is highly prevalent in people with
neuromuscular conditions, and is a consequence of reduced
general activity levels [136–138]. Aerobic training has not
been rigorously examined for people with IBM, although
one study did test a combined strength and aerobic home-
training programme [139]. Participants cycled three times a
week at 80 % maximum heart rate, with strength training
performed on alternate days. However, details in the paper
are limited; it seems that intensity and dose were low, with
participants cycling for short periods, and with strength train-
ing at a reduced frequency compared with previous studies
[133] and with low load. The authors revealed increased
cardiorespiratory fitness, but measured this using a submaxi-
mal exercise test which has known reliability problems [140].
Recently there has been much interest in high-intensity inter-
val training as a way to improve fitness without increasing
fatigue. One group has started to test this for IBM [141], but
full results are not yet available and safety is yet to be
established.
Other potential exercise interventions have not been inves-
tigated for IBM; for example, specific balance exercises for
falls prevention or exercises for weak upper-limb, hand, and
trunk muscles, all of which have a strong effect on functional
ability and quality of life. Timing of intervention has also not
been systematically tested—could strength training early in
the disease process slow or reduce functional impairment in
the later stages?
Unfortunately, increasing evidence for the safety and effi-
cacy of exercise has not reached the patient population. A
recent study found they spent less time exercising and report-
ed more barriers to exercise than controls. The most common
barriers were lack of energy and motivation, and concerns
about health, pain, and accelerating the degenerative process
[142]. Good-quality evidence is needed so people with IBM
can be confident their exercise prescription will lead to func-
tional improvement with minimum adverse effects.
Our group is investigating aerobic training in IBM regard-
ing fitness levels, muscle strength, and function, using a
randomised crossover design with training and control periods
[143]. Training consists of cycling three times a week for
twelve weeks at 60 to 80 % of heart-rate reserve. The primary
outcome measure is VO2 peak, with strength and function as
secondary outcomes. Aspects of the intervention including
engagement, motivation, psychological well-being, and the
patient experience will also be investigated, because these
are crucial for the opt imum uptake of exercise
recommendations.
Conclusion
These are exciting times for research in IBM. A large amount
of work has been undertaken in recent years to improve our
understanding of IBM and to enhance our capacity to opti-
mally diagnose and monitor the disease. Despite recent ad-
vances, the precise aetiology of the disease remains unknown
and the mechanisms of interaction between the different path-
ogenic models that have been proposed remain to be clarified.
There is no pharmacological treatment that has proved to be
efficacious in IBM clinical trials. However, the prospect is still
encouraging, with ongoing research developments and find-
ings from pre-clinical experiments being translated into new
clinical trials. IBM is a rare disease, and the development of
global strategies capable of fostering research collaboration
will be crucial to improve diagnosis, treatment, and care for
people with this debilitating disease.
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